BIOMUNE SYSTEMS INC
10KSB40, EX-27, 2001-01-16
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BIOMUNE SYSTEMS INC, 10KSB40, EX-23.2, 2001-01-16
Next: WEGENER CORP, 10-Q, 2001-01-16



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           1,780
<SECURITIES>                                   864,434
<RECEIVABLES>                                  781,414
<ALLOWANCES>                                   190,200
<INVENTORY>                                    168,040
<CURRENT-ASSETS>                               786,034
<PP&E>                                         170,427
<DEPRECIATION>                                 100,338
<TOTAL-ASSETS>                               1,733,793
<CURRENT-LIABILITIES>                          801,824
<BONDS>                                              0
                                0
                                    195,172
<COMMON>                                           971
<OTHER-SE>                                     735,826
<TOTAL-LIABILITY-AND-EQUITY>                 1,733,793
<SALES>                                        654,962
<TOTAL-REVENUES>                               654,962
<CGS>                                          427,476
<TOTAL-COSTS>                                5,190,752
<OTHER-EXPENSES>                               797,606
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             212,080
<INCOME-PRETAX>                              5,545,476
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          5,545,476
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 5,545,476
<EPS-BASIC>                                     (4.17)
<EPS-DILUTED>                                   (4.28)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission